Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN5 | P54829 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6597047 | 0.86 | SMN1; SMN2 (0.38) | TSHR | |
| SCHEMBL6598149 | 0.83 | NOS2 (0.32) | ALOX15ALOX12TSHR | |
| SCHEMBL6593588 | 0.83 | SCN9A (0.30) | — | |
| SCHEMBL6589023 | 0.82 | L3MBTL1 (0.32) | — | |
| SCHEMBL6598100 | 0.82 | HPGD (0.38) | KMT2A | |
| SCHEMBL6594864 | 0.80 | CYP2C9 (0.39) | ALOX15ALOX12KMT2AKDM4ETSHR | |
| SCHEMBL6596317 | 0.74 | GAA (0.33) | ALOX15ALOX12 | |
| SCHEMBL6596836 | 0.70 | CYP3A4 (0.38) | ALOX15KMT2ATSHR | |
| SCHEMBL5841811 | 0.69 | SMN1; SMN2 (0.30) | — | |
| SCHEMBL6594271 | 0.67 | RORC (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1120411-B1 | 4-Aryl-1,2,4-triazolidinedione derivatives and their use as herbicides | BAYER CROPSCIENCE AG (DE) | 2004-09-22 | — | — | EP | disclosed |
| US-6743755-B2 | HERBICIDAL COMPOSITION WHICH HAS A CONTENT OF AT LEAST ONE N-ARYL NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OF THE GENERAL METHOD OF COMBATING UNDESIRABLE PLANTS WHICH COMPRISES ALLOWING AN N-ARYL NITROGEN-CONTAINING HETEROCYCLIC | BAYER AKTIENGESELLSCHAFT (DE) | 2004-06-01 | — | — | US | disclosed |
| US-20030208073-A1 | Substituted N-aryl nitrogen-containing heterocyclic compounds | LINKER KARL-HEINZ (DE) | 2003-11-06 | — | — | US | disclosed |
| US-20030144522-A1 | Substituted N-aryl nitrogen-containing heterocyclic compounds | LINKER KARL-HEINZ (DE) | 2003-07-31 | — | — | US | disclosed |
| US-6426318-B1 | KILLING WEEDS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-07-30 | — | — | US | disclosed |
| EP-1120411-A2 | 4-Aryl-1,2,4-triazolidinedione derivatives and their use as herbicides | BAYER AG (DE) | 2001-08-01 | — | — | EP | disclosed |
| US-6162765-A | Substituted N-aryl nitrogen-containing heterocyclic compounds | BAYER AKTIENGESELLSCHAFT (DE) | 2000-12-19 | — | — | US | disclosed |
| EP-0797573-A1 | 3-ARYL-1,2,4-TRIAZOLE DERIVATIVES WITH HERBICIDAL PROPERTIES | BAYER AG (DE) | 1997-10-01 | — | — | EP | disclosed |
| WO-1996018618-A1 | 3-ARYL-1,2,4-TRIAZOLE DERIVATIVES WITH HERBICIDAL PROPERTIES | BAYER AKTIENGESELLSCHAFT (DE) | 1996-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030208073-A1 | Substituted N-aryl nitrogen-containing heterocyclic compounds | NAT1, CYP1B1, CYP1A1 | PTPN5 1012/4885ALOX15 4224/4885ALOX12 3568/4885 |
| US-20030144522-A1 | Substituted N-aryl nitrogen-containing heterocyclic compounds | NAT1, CYP1B1, CYP1A1 | PTPN5 1012/4885ALOX15 4224/4885ALOX12 3568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.